Bruce Levine Speaks on the Future of CAR-T Therapies
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to Treat Liver Fibrosis
the Mitchell Lab has developed a new class of anisimide-functionalized lipids that enables targeted delivery of lipid nanoparticles (LNPs) to activated fibroblasts in the liver.
Fake
This technology is an intracerebral drug delivery system that consists of three flexible, retractable microcannulas housed within a single central catheter.
Mitchell Lab’s Targeted Prenatal Therapy for Mothers and Their Babies Addresses Gap in Health Equity
The researchers’ successful trials in mice show that the technology may potentially lead to promising treatment options for humans with pre-eclampsia.
Penn Medicine, CHOP receive $25M anonymous gift to accelerate research in rare genetic brain disorders
The donation will establish the Center for Epilepsy and Neurodevelopmental Disorders, which will initially focus on developing therapies for disorders related to genetic mutations that are linked to a
Eidos LGBTQ+ Health Initiative Support Advances in LGBTQIA+ Health Startups
The goal of the partnership is to support founders and entrepreneurs with in-depth LGBTQ+ health knowledge and research expertise.
fake troo
Koo and Steager's magnetic, scalable, tether-free robotic devices can be used for diagnostics via retrieval and sampling of biofilms associated with infectious diseases.
Penn Scientists New Research Shows That a CAR-T gel Treatment May Be Able to Kill Residual Cancer Cells Left Over from Surgery
In the study, Penn scientists added CAR-T cells to a gel designed to prevent bleeding after surgery and applied it to the surgical wounds of mice after they had hard-to-treat tumors resected.
PCI Highlights mRNA Innovation at JPM
On January 9th, 2023 PCI was proud to present a star-studded program entitled “The Future of mRNA Technology” at Wharton San Francisco during the JP Morgan Healthcare Conference.